Xtant Medical Holdings, Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Xtant Medical performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Xtant Medical, based in Belgrade, Montana, creates technology for orthopedic and spinal surgeries. They provide the hardware—like screws, plates, and rods—and the biological materials, such as bone grafts, that surgeons use to fix back and neck issues. They trade on the NYSE American exchange under the ticker XTNT. Last year, the company generated $105.5 million in revenue, a 15% increase driven by their growing product lineup.

2. Financial Performance & Health

The company is currently in a transition phase. Here is the most important update:

• A One-Time Boost: In 2025, Xtant earned $18.7 million from a one-time intellectual property deal. This payment will not happen again in 2026, which will make year-over-year comparisons look difficult.
• Asset Sales: To focus on their most profitable products, they sold their "Coflex" and "CoFix" lines and their international hardware business for $21.4 million. They used this cash to pay down high-interest debt. They ended the year with about $15 million in cash.
• The 2026 Challenge: Changes in how insurance and Medicare pay for their "SimpliMax" bone graft will likely reduce revenue by $5 million to $7 million in 2026. This shift will also likely lower their profit margins from 68% to between 62% and 64%.

3. Major Wins and Strategic Shifts

Xtant is pivoting toward growth by launching new products, such as nanOss Strata and CollagenX. Their strategy includes:

1. New Products: They are focusing on high-profit, proprietary biological materials, which now make up 60% of their revenue.
2. Expanding Sales: They plan to grow their network of independent sales agencies from 120 to over 150 by the end of 2026 to reach more hospitals.
3. Acquisitions: They plan to use their improved cash position to buy smaller medical device companies and sell those products through their existing network.

4. Key Risks

Keep these risks in mind:

• Slower Growth: Because of the lost license deal and insurance payment changes, management expects 2026 revenue growth to be flat or in the low single digits.
• Customer Concentration: Their top 10 customers provide 35% of their revenue. Losing a major contract could significantly hurt sales.
• Size: With a market value under $200 million, Xtant lacks the resources of giants like Medtronic or Stryker. They are very sensitive to insurance companies choosing cheaper alternatives over Xtant’s premium products.

5. Future Outlook

Xtant is narrowing its focus to its core business. While they cleared debt and raised cash, 2026 will be a rebuilding year. They hope new products will eventually replace the lost revenue. Management aims to be cash-flow positive by the end of 2026, assuming their new products grow by 10%.

Investor Takeaway: Xtant is currently trading as a "show me" story. If you are considering an investment, watch their ability to scale their new biological product lines and hit their goal of being cash-flow positive by the end of 2026. Because 2026 is a transition year with lower expected growth, the stock may experience volatility as the market adjusts to the loss of the one-time licensing revenue.